CONFERENCE AGENDA

Online registrations	08:15 - 08:45
Opening note by MarketsandMarkets	08:45 - 08:55
Opening remarks by Chairperson	08:55 - 09:00
CELL CULTURE & BIOPRODUCTION
Process Design for AAV-based Gene & Cell Therapy Vectors towards Commercialization Barbara Kraus, Head of Gene Therapy Process Development, Takeda	09:00 - 09:30
Developing a clinical grade manufacture of CYAD-101, a non-gene edited allogeneic NKG2D-based CAR T cell therapy for the treatment of solid malignancies Emilie Gauthy, R&D Manager CMC and Process Development, Celyad	09:30 - 10:00
Introducing Stem Cell-Specific Dosing for Better Stem Cell and Gene Therapies James L. Sherley, Founder & CEO, Asymmetrex LLC	10:00 - 10:30
UPSTREAM BIOPROCESSING & MANUFACTURING
Understanding the Regulatory and practical benefits of clonally-derived workflows Duncan Borthwick, Global Marketing Manager, Solentim	10:30 - 11:00
Networking break & one on one meeting	11:00 - 11:20
Automation and digitalization of cell therapy manufacturing Hemant Dhamne , Head of Vector and CAR-T Cell Processing, Immuneel Therapeutics Pvt Ltd	11:20 - 11:50
A new single-cell cloning and imaging platform and scale-down bioreactors for generating high producer cell lines with >99.99% monoclonality Elly Sinkala, Lead Application Scientist, Cytena	11:50 - 12:20
Developing the world’s first triple antigen Virus Like Particle (VLP) against SARS CoV-2 virus, and oral delivery Prabuddha Kundu, Co-founder & Managing Director, Premas Biotech	12:20 - 12:50
Closing Remarks	13:20 - 13:25
End of Day 1	13:25 - 13:25

Online registrations	08:15 - 08:45
Opening note by MarketsandMarkets	08:45 - 08:55
Opening remarks by Chairperson Stefano Baila, Director of Operations & Business Development, Anemocyte	08:55 - 09:00
DOWNSTREAM BIOPROCESSING & MANUFACTURING
Stem Cells & Regenerative Medicine : An Emerging Opportunity for Indian Life Sciences & Health-Care Ecosystem Vishal Gandhi, Founder & CEO, Biorx Venture Advisors Pvt. Ltd	09:00 - 09:20
About the hurdles of cell therapy manufacturing for a clinical trial Jenny Prange, Chief Scientific Officer, MUVON Therapeutics AG	09:20 - 09:50
Stem cell & Regenerative Medicine in Infertilty Prabhu Chandra Mishra, Head, Department of Regenerative Medicine, Stemmax Research & Therapeutics Pvt Ltd	09:50 - 10:20
Networking & One on one meeting	10:20 - 10:45
ANALYTICS, REGULATORY & SUPPLY CHAIN
Cell therapy standardisation: Elsa Branches, Interim Head-Advanced Therapies, Medicines and Healthcare Products Regulatory Agency	10:45 - 11:15
Overcoming the bottle neck of autologous manufacturing by adaptive culturing and sensor based automation Ohad Karneili, Founder & CEO, Adva Biotechnology	11:15 - 11:45
Plasmids and other underestimated challenges and opportunities for cell gene-modification Stefano Baila, Director of Operations & Business Development, Anemocyte	11:45 - 12:15
End to end logistics and inventory management of biotherapeutics Fabio D'Agostino, Venture Partner-Cell Gene Therapy expert, Claris Ventures SGR SpA	12:15 - 12:45
Closing Remarks	12:45 - 12:50
End of Conference	12:50 - 12:50